Navigation Links
Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
Date:2/4/2009

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 11th Annual BIO CEO & Investor Conference. The details are as follows:

    Corporate Presentation:
    Date:  Monday, February 9, 2009
    Time:  3:45 p.m. - 4:15 p.m. Eastern
    Location: Waldorf Astoria, Astor Room, New York
    Speaker: Graham Cooper, Chief Financial Officer

    Panel Discussion:
    Feeding the Need for New Treatments in Obesity
    Date:  Monday, February 9, 2009
    Time:  11:00 a.m. - 12:10 p.m. Eastern
    Location: Waldorf Astoria, East Foyer, New York
    Speaker: Dr. Dennis Kim, Senior Vice President, Corporate Development

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
2. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
3. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
6. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
8. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
9. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Noom Inc. , the ... to offer fully Spanish behavior change programs that ... diabetes prevention and healthy weight management programs ... lifestyle interventions among Hispanic Americans who are at ... food database, program-specific curriculum content and program features ...
(Date:1/17/2017)... Jose, CA (PRWEB) , ... January 17, 2017 , ... ... cultivate a balanced, peaceful and healthy lifestyle, announced today the official launch of its ... and frees the mind. , In development for over a year, the ...
(Date:1/17/2017)... Ohio , Jan. 17, 2017  On January ... the 35th Annual J.P. Morgan Healthcare Conference in ... Joseph D. Kittle, Jr. , spoke to pharmaceutical leaders ... developed by ProclaRx to break down and destroy biofilms.  ... protect bacteria and prevent antibiotics and the body,s immune ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... ... a new service providing complete end-to-end genome assemblies to researchers around the globe. ... eliminates a major obstacle in answering a wide range of scientific questions. ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):